FDMT 4D Molecular Therapeutics

4DMT to Participate in Upcoming Investor Conferences

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings.

Leerink's Global Biopharma Conference 2025

Presentation Date: Tuesday, March 11, 2025

Presentation Time: 10:00 a.m. ET

Webcast Link: 

Barclays Global Healthcare Conference 2025

Presentation Date: Wednesday, March 12, 2025

Presentation Time: 10:00 a.m. ET

Webcast Link: 

Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at .

About 4DMT

4DMT is a late-stage biotechnology company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of directed evolution with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our lead program 4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) targeted to the retina with a single, safe, intravitreal injection. Our second core program is 4D-710, which is the first known genetic medicine to demonstrate, in the lungs of people with cystic fibrosis (CF), successful delivery and expression of the CFTR transgene and initial clinical activity signals after aerosol delivery of a gene therapy. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.

Learn more at and follow us on .

Contacts:

Media:

Jenn Gordon

dna Communications

Investors:

Julian Pei

Head of Investor Relations and Corporate Finance



EN
19/02/2025

Underlying

FDMT4D Molecular Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 4D Molecular Therapeutics

 PRESS RELEASE
Free
FDMT 4D Molecular Th...

4DMT to Participate in Upcoming Investor Conferences

4DMT to Participate in Upcoming Investor Conferences EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in March. TD Cowen 46th Annual Health Care Conference Presentation Date:Tuesday, March 3, 2026Presentation Time:10:3...

February 19, 2026 1 EN
 PRESS RELEASE
Free
FDMT 4D Molecular Th...

4DMT Announces New Employment Inducement Grants

4DMT Announces New Employment Inducement Grants EMERYVILLE, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on February 10, 2026, the compensation committee of the Company’s board of directors granted nine new non-executive employees 124,200 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 ...

February 13, 2026 1 EN
 PRESS RELEASE
Free
FDMT 4D Molecular Th...

4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-15...

4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections 4FRONT-1 overenrolled and expected to exceed 500 patients randomized, reflecting strong interest from investigators and patients Topline data from 4FRONT-1 expected in H1 20274FRONT-2 global site activation momentum continues, with enrollment completion on track for H2 2026 and topline data expected in H2 2027 EMERYVILLE, Calif., Feb. 09, 2026 (G...

February 9, 2026 1 EN
 PRESS RELEASE
Free
FDMT 4D Molecular Th...

4DMT Announces New Employment Inducement Grants

4DMT Announces New Employment Inducement Grants EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026, the compensation committee of the Company’s board of directors granted four new non-executive employees 23,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Em...

January 17, 2026 1 EN
 PRESS RELEASE
Free
FDMT 4D Molecular Th...

4DMT Provides Company Update and Anticipated Development Milestones fo...

4DMT Provides Company Update and Anticipated Development Milestones for 2026 Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as of January 6, 20264D-150 PRISM wet AMD 2-year Phase 2b data expected mid-20264D-150 DME global Phase 3 trial initiation expected Q3 2026; 2-year SPECTRA Phase 1/2 data expected H2 2026Appointed Glenn Sblendorio to Board of Directors, adding deep commercial and operating experience, including in retina therapeuticsComp...

January 7, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch